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Crystallographic studies showed that epider-
mal growth factor (EGF) receptor activation in-
volves major domain rearrangements. Without
bound ligand, the extracellular region of the
receptor (sEGFR) adopts a ‘‘tethered’’ configu-
ration with its dimerization site occluded by ap-
parently autoinhibitory intramolecular interac-
tions. Ligand binding causes the receptor to
become ‘‘extended,’’ breaking the tether and
exposing the dimerization site. Using small-
angle X-ray scattering (SAXS), we confirm that
the tethered and extended conformations are
also adopted in solution, and we describe
low-resolution molecular envelopes for an in-
tact sEGFR dimer. We also use SAXS to monitor
directly the transition from a tethered to ex-
tended configuration in the monomeric extra-
cellular regions of ErbB3 and a dimerization-
defective EGFR mutant. Finally, we show that
mutating every intramolecular tether interaction
in sEGFR does not greatly alter its confor-
mation. These findings explain why tether mu-
tants fail to activate EGF receptor and provide
new insight into regulation of ErbB receptor
conformation.
INTRODUCTION
The epidermal growth factor receptor (EGFR) has long
been studied as a prototypical receptor tyrosine kinase
(RTK). EGFR was one of the first receptors for which the
importance of ligand-induced receptor dimerization for
transmembrane signaling was established (Schlessinger,
2000) and was the first cell-surface receptor to be linked
directly to human cancer (de Larco and Todaro, 1978).
Recent crystallographic studies have provided sophisti-
cated structural views of both the extracellular ligand-
binding region of EGFR (Ferguson et al., 2003; Garrett
et al., 2002; Ogiso et al., 2002) and its intracellular tyrosine
kinase domain (Stamos et al., 2002; Wood et al., 2004;
Zhang et al., 2006). Structures have also been determined942 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd Allfor the extracellular regions of ErbB2 (HER2/Neu) (Cho
et al., 2003; Garrett et al., 2003), ErbB3 (Cho and Leahy,
2002), and ErbB4 (Bouyain et al., 2005): all four members
of the ErbB family in mammals (Linggi and Carpenter,
2006). These structural studies have provided consider-
able insight into how growth factor binding regulates re-
ceptor dimerization and activation (Burgess et al., 2003;
Leahy, 2004; Linggi and Carpenter, 2006; Zhang et al.,
2006), although many key mechanistic questions remain
unanswered.
Ligand-induced dimerization of most RTKs and cyto-
kine receptors involves direct participation of the ligand
in the dimer interface, where it often ‘‘bridges’’ the two
receptor molecules (Schlessinger, 2000; Stroud and
Wells, 2004). By contrast, the ligand makes no direct
contributions in an activated EGFR dimer. The EGF-
binding sites are quite remote from the dimer interface,
and EGFR dimerization is mediated entirely by receptor-
receptor interactions (Burgess et al., 2003; Garrett et al.,
2002; Ogiso et al., 2002). A single cysteine-rich domain
(domain II, green in Figure 1) dominates the interface be-
tween two EGFR molecules and contributes a critical
‘‘dimerization arm’’ (Garrett et al., 2002; Ogiso et al.,
2002). In the absence of bound ligand, this domain II di-
merization arm is buried by intramolecular interactions
with domain IV (red in Figure 1)—giving rise to a ‘‘teth-
ered,’’ or autoinhibited, configuration for the monomeric
extracellular region shown at the left of Figure 1 (Cho
and Leahy, 2002; Ferguson et al., 2003). EGFR activation
involves a single EGF molecule binding simultaneously to
both domains I and III (blue and yellow in Figure 1) of
EGFR, causing the extracellular region of the receptor
to adopt an ‘‘extended’’ configuration in which the intra-
molecular tether between domains II and IV is broken
(Garrett et al., 2002; Ogiso et al., 2002). This extension
also exposes the domain II dimerization arm, which
drives receptor-receptor interactions as shown on the
right of Figure 1 (Burgess et al., 2003; Ferguson et al.,
2003).
Despite the implications of Figure 1, mutations de-
signed to disrupt domain II/IV tether interactions in
EGFR do not promote ligand-independent receptor di-
merization in vitro or activation at the cell surface (Dawson
et al., 2005; Elleman et al., 2001; Ferguson et al., 2003;
Mattoon et al., 2004; Walker et al., 2004). The mutated re-
ceptors maintain their ability to be activated by ligandrights reserved
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Conformations of ErbB Receptor EctodomainsFigure 1. Mechanism of EGF-Induced ‘‘Extension’’ of the EGFR Extracellular Region
Without bound ligand, the EGFR extracellular region adopts the conformation shown at left (PDB ID 1NQL or 1YY9), with an intramolecular ‘‘tether’’
(circled in black) formed between domains II and IV. Upon binding of EGF to both domain I and domain III, the domain II/IV tether is broken, and the
receptor adopts an extended conformation (right). With the domain II dimerization arm exposed, EGF-bound sEGFR dimerizes as shown on the right-
hand side (Burgess et al., 2003), with the majority of contacts mediated by the dimerization arm (ringed with black oval). Domain I is colored blue,
domain II is green, domain III is yellow, domain IV is red, and EGF is magenta. The approximate location of the primary ‘‘hinge’’ between domains
II and III for the tethered-to-extended transition is marked as a black circle in the left-hand panel.(showing that the mutations do not impair dimerization
contacts), but removal of the tether does not elevate basal
activity. To explain this finding, three main possibilities
can be considered. First, the EGFR extracellular region
might not adopt the crystallographically observed teth-
ered conformation in solution. Second—if the tether
does form—mutations designed to disrupt the domain
II/IV tether may not cause the expected changes in con-
formation of the EGFR extracellular region. Third, simply
exposing the domain II dimerization arm may not be suf-
ficient to promote detectable EGFR activation in the
absence of additional ligand-induced conformational
changes in domain II (Dawson et al., 2005). To distinguish
between these possibilities, we used small-angle X-ray
scattering (SAXS) to analyze the structural properties in
solution of isolated extracellular regions from EGFR
(wild-type and mutated) and other ErbB receptors. We
can monitor the ligand-induced tethered-to-extended
transition in ErbB receptor extracellular regions directly
with SAXS. We show that domain IV mutations thought
to disrupt the intramolecular tether do not promote adop-
tion of the extended configuration, and we identify other
likely contributions to the tethered conformation. Our find-
ings provide new insight into the conformational equilibria
of ErbB receptor extracellular regions that will be valuable
for predicting the likely effects of mutations identified in
different disease states.Structure 15, 942–RESULTS
The EGFR Extracellular Region Is Tethered
in Solution—sErbB2 Is Extended
To investigate the likely utility of X-ray scattering studies
for analyzing the conformations of ErbB receptor extracel-
lular regions in solution, we used the program CRYSOL
(Svergun et al., 1995) to calculate expected SAXS param-
eters from the crystal structures of tethered (unliganded)
monomeric sEGFR and extendedmonomeric sErbB2 (Ta-
ble 1, right hand columns). The calculated maximum di-
mension (Dmax) of the molecule increases from 95–100 A˚
for tethered sEGFR (Ferguson et al., 2003; Li et al.,
2005b) to 125 A˚ for the extended human sErbB2 structure
(Cho et al., 2003). This difference should be discernible
readily in SAXS experiments. Differences in radii of gyra-
tion (Rg) are smaller, with values of 33.5 A˚ and 34.8 A˚ for
the two available tethered sEGFR structures (Ferguson
et al., 2003; Li et al., 2005b), and 34.8 A˚ for extended
sErbB2 (Cho et al., 2003).
As summarized in Table 1 (left), the experimentally de-
termined Dmax values for wild-type sEGFR (105 A˚) and
sErbB2 (130 A˚) agree very well with those predicted
from crystal structures, supporting the hypothesis that in
solution, sEGFR and sErbB2 adopt the crystallographi-
cally defined tethered and extended average conforma-
tions, respectively. Experimentally determined Rg values954, August 2007 ª2007 Elsevier Ltd All rights reserved 943
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Conformations of ErbB Receptor EctodomainsTable 1. Radii of Gyration, Rg, and Maximum Dimension, Dmax, Values for sErbB Proteins from SAXS Studies and
Crystal Structures
Experimental (from SAXS) Calculated (from Crystal Structures or Models)
sEGFR 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
sEGFR Coordinates 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
Wild-type – EGF 1-mer 35.4 ± 0.11 105 ± 5 tetheredb 1NQLc 1-mer 33.5 95
sEGFRY251A/R285S  EGF 1-mer 35.7 ± 0.04 105 ± 5 tethered 1NQL + sugard 1-mer 36.6 105
sEGFRY251A/R285S + EGF 1-mer 37.8 ± 0.31 130 ± 5 tethered 1YY9e 1-mer 34.8 100
sEGFR563/566/585*  EGF 1-mer 36.2 ± 0.04 100 ± 5 tethered 1YY9 + sugard 1-mer 38.1 105
sEGFR563/566/585*/D575-584EGF 1-mer 34.8 ± 0.24 100 ± 5 Dimer + EGF modelf 2-mer 43.7 125
wild-type + EGF 2-mer 46.1 ± 0.89 145 ± 5 Dimer + EGF modelf + sugard 2-mer 46.8 140
sErbB2 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
sErbB2 Coordinates 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
Wild-type 1-mer 38.2 ± 0.15 130 ± 5 extended 1N8Zg 1-mer 34.8 125
Wild-type deglycosylateda 1-mer 37.6 ± 0.14 125 ± 5 extended 1N8Z + sugard 1-mer 36.6 125
sErbB3 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
sErbB3 Coordinates 1-mer/
2-mer
Rg
(A˚)
Dmax
(A˚)
sErbB3  NRG1b 1-mer 39.4 ± 0.19 105 ± 5 tethered 1M6B 1-mer 37.0 110
sErbB3 + NRG1b 1-mer 40.0 ± 0.04 130 ± 5 tethered 1M6B+sugard 1-mer 38.5 115
aDeglycosylated sErbB2 was prepared as described (Cho et al., 2003).
b Since two structures of tethered sEGFR exist (1NQL and 1YY9), calculated parameters are listed for both.
c Bound EGF was omitted from the 1NQL (sEGFR) coordinates used for calculating predicted SAXS data.
d Sugars were modeled onto each crystal structure as described in Experimental Procedures.
e Bound cetuximab was omitted from the 1YY9 (sEGFR) coordinates used for calculating predicted SAXS data.
f The sEGFR dimer model used is that shown in Figure 1 (based on 1IVO and 1NQL) and is taken from (Ferguson et al., 2003).
g Bound trastuzumab was removed from the 1N8Z (sErbB2) coordinates used for calculating predicted SAXS data.were slightly higher than those computed from the crystal
structure models (Table 1), probably as a result of the con-
tribution of attached carbohydrates to X-ray scattering.
Our SAXS studies utilized fully glycosylated proteins se-
creted from Sf9 or S2 cells, whereas the crystal structure
models used to compute Dmax and Rg values typically in-
clude at most one saccharide unit at each glycosylation
site. To assess the impact of glycosylation on the SAXS-
derived parameters, we used two approaches. First, we
approximated fully glycosylated sEGFR and sErbB2 by
modeling Man9GlcNAc2 oligosaccharides onto each of
the predicted glycosylation sites in the respective crystal-
lographic coordinate files and recalculated Dmax and Rg
values with CRYSOL. As reported in the right-hand part
of Table 1, this manipulation increased Dmax by <10%
and brought computed Rg values to within 1.0–1.5 A˚ of
those observed experimentally. Second, we also com-
pared scattering by fully glycosylated sErbB2 with protein
that had been deglycosylated with endoglycosidase H
(Cho et al., 2003). Deglycosylation reduced Dmax by just
5 A˚ and Rg from 38.2 A˚ to 37.6 A˚—arguing that the lack
of explicit consideration of oligosaccharides does not
invalidate our conclusions.
Additional average shape information can be gleaned
from pair-distance distribution (or P(r)) curves, which de-
scribe the length distribution of all interatomic vectors in944 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd Alla molecule and are obtained by inverse Fourier transform
of the scattered intensity. P(r) curves have quite different
characteristics for sEGFR and sErbB2 (Figures 2A and
2B). For unliganded sEGFR, the experimental P(r) curves
(Figure 2A, black squares) and those calculated from
crystal structures (Figure 2B, black curve) have two peaks
(or a clear shoulder) that suggest a structure with two spa-
tially distinct parts. As illustrated in Figure 2C, domains I
plus II (blue and green) in the tethered configuration are
likely to constitute one of these parts, and domains III
plus IV (yellow and red) the other part. With this model,
the primary peak centered at 40 A˚ in the P(r) curves
shown in Figures 2A and 2B (black traces) would repre-
sent the length distribution of interatomic vectors within
the domain I/II and domain III/IV parts of tethered sEGFR.
The peak/shoulder at 60–65 A˚ would reflect the length
distribution of vectors between one atom in domain I/II
and another in the domain III/IV part. These characteris-
tics are shared by P(r) curves calculated from crystal
structures of all tethered ErbB receptor extracellular re-
gions (Figure S1A, see the Supplemental Data available
with this article online). For sErbB2, by contrast, both
the experimental (Figure 2A, red triangles) and calculated
(Figure 2B, red curve) P(r) curves are dominated by a sin-
gle peak centered at 35–40 A˚, consistent with the more
globular nature of the domain I/II/III part of extendedrights reserved
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Conformations of ErbB Receptor EctodomainsFigure 2. SAXS Distinguishes Tethered
and Extended Configurations in Solution
(A) Experimental P(r) curves for ligand-free
sEGFR (black squares) and sErbB2 (red trian-
gles). Rg and Dmax values are listed in Table 1.
(B) P(r) curves calculated from the crystallo-
graphic coordinates of tethered sEGFR (Li
et al., 2005b) and extended sErbB2 (Cho
et al., 2003) (black and red dashed lines, re-
spectively). Coordinates used to generate
these P(r) curves were from PDB entries
1YY9 (sEGFR) and 1N8Z (sErbB2), from which
bound antibody coordinates were removed
andMan9GlcNAc2 moieties were added as de-
scribed in Experimental Procedures. Overlays
of calculated and experimental P(r) curves are
shown in Figure S2, and the influence of mod-
eled oligosaccharides is illustrated in FigureS1.
(C) Space-filling models of ligand-free sEGFR
and sErbB2, with domains colored as in Fig-
ure 1.
(D) Guinier plots of ln I(Q) against Q2 for SAXS
data acquired for unliganded sEGFR and
sErbB2, showing the linear Guinier region
(with QRg % 1.22) from which Rg can be
estimated.sErbB2 (Figure 2C). The tail at larger distances (100 A˚) is
likely to represent interatomic vectors between the globu-
lar region and the extended domain IV. As shown in
Figure S1B, the presence or absence of modeled oligo-
saccharides does not significantly affect qualitative inter-
pretation of the P(r) curves. Experimental and calculated
P(r) curves are directly overlaid in Figure S2, and repre-
sentative Guinier plots are shown in Figure 2D.
For clearer visualization of the shape information held in
our experimental SAXS data, we calculated low-resolution
molecular envelopes for unliganded sEGFR and sErbB2.
We used DAMMIN (Svergun, 1999), which employs a sim-
ulated annealing procedure to identify spatial arrange-
ments of dummy atoms (spheres) that can account for
the experimentally observed scattering data (Figure 3A).
Models from multiple DAMMIN runs were superimposed
and averaged with the program DAMAVER (Volkov and
Svergun, 2003) to generate most probable molecular en-
velopes as described in Experimental Procedures (Koch
et al., 2003). The tethered sEGFR and sErbB2 crystal
structures can be docked readily into their respective
low-resolution envelopes derived from our solution SAXSStructure 15, 942studies (Figures 3Band 3C). The tethered sEGFR structure
cannot be accommodated by the envelope derived from
SAXSstudiesof sErbB2.Conversely, theextendedsErbB2
crystal structure cannot be fit into the SAXS envelope
obtained for sEGFR. These findings, together with the co-
incidence of computed and experimental Dmax values, Rg
values (Table 1), and P(r) curve characteristics (Figures
2A and 2B) argue that sEGFR is indeed predominantly
tethered in solution, whereas sErbB2 is predominantly ex-
tended. The different configurations of these proteins ob-
served crystallographically therefore appear to reflect the
inherent properties of each receptor extracellular region
andnot simply conformations that are ‘‘trapped’’ byprefer-
ential crystallization. It is important to note that sEGFR and
sErbB2 almost certainly explore a range of conformations
in solution (Burgess et al., 2003), and our SAXS studies re-
port only on the average of this ensemble. Based on qual-
itative assessment of calculated P(r) curves, we estimate
that up to 20% of sEGFR could exist in untethered con-
formations in the absence of ligand. SAXS does not allow
a more precise estimate of this proportion or of the nature
of the untethered states.–954, August 2007 ª2007 Elsevier Ltd All rights reserved 945
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Conformations of ErbB Receptor EctodomainsFigure 3. Low Resolution Molecular
Envelopes for Unliganded sEGFR and
sErbB2
(A) Scattering profiles, with I(Q) plotted against
Q are shown for unliganded sEGFR (left, black
squares) and sErbB2 (right, red triangles). The
contrasting solid curve drawn through the
scattering data is the best-fit simulated scat-
tering profile from a single representative
DAMMIN run (c2 = 1.75 for sEGFR, and c2 =
2.16 for sErbB2 for the fits shown).
(B) Surface rendering of the most probable/av-
erage low resolution SAXS-derived model for
unliganded sEGFR in solution, generated with
DAMFILT and DAMAVER (Volkov and Svergun,
2003) to analyze the output frommultiple DAM-
MIN runs as described in Experimental Proce-
dures. The molecular envelope is shown in
a blue mesh, and the crystallographic coordi-
nates of tethered sEGFR have been docked
into the envelope with the program Situs (Wrig-
gers and Birmanns, 2001). Two orthogonal
views are shown, rotated 90 about a vertical
axis. Domains I, II, III, and IV are colored blue,
green, yellow, and red—as in previous repre-
sentations of sErbB structures.
(C) Low-resolution molecular envelope for
sErbB2 generated as in (B), with the sErbB2
structure docked into the envelope. Structures
in (B) and (C) are aligned vertically with respect
to one another, using domain III (yellow) as ref-
erence. Two orthogonal views are shown.Ligand-Induced Extension of ErbB Receptor
Extracellular Regions Observed with SAXS
A primary goal in this study was to monitor directly the li-
gand-induced transition of an ErbB receptor extracellular
region from a largely tethered configuration to an ex-
tended form. We first analyzed this transition with the
ErbB3 extracellular region (sErbB3), taking advantage of
previous observations that ErbB3 binds NRG1b without
dimerizing (Berger et al., 2004; Cho and Leahy, 2002; Fer-
guson et al., 2000; Landgraf and Eisenberg, 2000) and that
fully glycosylated unliganded sErbB3 is entirely mono-
meric (Ferguson et al., 2000). Without bound ligand,
sErbB3 crystallized in a tethered configuration very similar
to that described above for sEGFR (Cho and Leahy, 2002).
However, no structural information currently exists for an
sErbB3/ligand complex. As shown in Figure 4A (closed
green circles), SAXS studies of unliganded sErbB3 yield
the bimodal P(r) curve characteristic of the tethered con-
figuration, with a Dmax value of 105 A˚ and Rg of 39.4 A˚.
These values agree well with those computed from the
crystal structure (Table 1). Following NRG1b binding, the
P(r) curve of monomeric sErbB3 (open green circles in
Figure 4A) closely resembles that seen for the extended
sErbB2 molecule, dominated by a single peak (with an946 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd Alladditional tail centered at 100 A˚). Dmax is also increased
to 130 A˚, further suggesting that the NRG1b-bound
sErbB3 molecule becomes extended. DAMMIN-derived
molecular envelopes (Figure 4B) confirm that sErbB3
exists predominantly in a tethered configuration in the
absence of ligand but adopts an ErbB2-like extended
monomeric conformation when bound to NRG1b.
We were also able to monitor EGF-induced conforma-
tional changes in a mutated form of sEGFR that remains
monomeric following EGF binding. Mutating Y251 and
R285 (in domain II) to alanine and serine, respectively, dis-
rupts key intermolecular interactions that are involved in
EGFR dimerization and activation (Ogiso et al., 2002) but
reduces EGF-binding affinity by only 4-fold (Dawson
et al., 2005) and does not disrupt the intramolecular tether
(Ferguson et al., 2003). Both SAXS and our previous ana-
lytical ultracentrifugation studies (Dawson et al., 2005)
showed that EGF binding does not induce dimerization
of sEGFRY251A/R285S. In the absence of bound ligand,
sEGFRY251A/R285S has precisely the same Dmax and Rg
values as measured for tethered wild-type sEGFR (Table
1), and gives an almost identical P(r) curve (Figure 4C,
filled blue squares). Upon EGF binding, the Dmax mea-
sured for sEGFRY251A/R285S increases to 130 A˚, and Rgrights reserved
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Conformations of ErbB Receptor EctodomainsFigure 4. Conformational Changes in sEGFR and sErbB3 upon Ligand Binding
(A)P(r) curves for sErbB3 in the absence (filled green circles) and presence (open green circles) of its ligand, NRG1b (added at a 1.2-foldmolar excess).
NRG1b binding changes the P(r) curve from one that resembles tethered sEGFR to one that resembles extended sErbB2, andDmax increases similarly
(see Table 1). Note that sErbB3 does not dimerize upon NRG1b binding (Ferguson et al., 2000).
(B) SAXS-derivedmolecular envelopes of sErbB3 in the absence (left) and presence (right) of NRG1b indicate a NRG1b-induced transition from a teth-
ered to extended configuration of the sErbB3 monomer. The tethered sErbB3 structure (PDB entry 1M6B) is docked into the left-hand envelope, and
sErbB2 is docked into the right-hand envelope.
(C) ExperimentalP(r) curves for a dimerization-deficient mutant of sEGFR, in which key dimerization contact sites aremutated (Y251A/R285S) without
affecting tether formation. In the absence of EGF (filled blue squares), sEGFRY251A/R285S gives a P(r) curve similar to that seen for tethered wild-type
sEGFR. In the presence of excess EGF (open blue squares), the P(r) curve resembles that seen for extended sErbB2. Previous studies have shown
that sEGFRY251A/R285S does not dimerize upon EGF binding (Dawson et al., 2005; Ogiso et al., 2002).
(D) SAXS experiments with sEGFRY251A/R285S give molecular envelopes that accommodate the tethered sEGFR structure in the absence of EGF (left),
but only accommodate an extended sErbB configuration (sErbB2 is shown) in the presence of EGF. Thus, sEGFRY251A/R285S is an extendedmonomer
when bound to EGF.
(E) P(r) curves for different extended sErbB structures are overlaid to illustrate similarity. Unliganded sErbB2 (red dashed line) is extended, as is an
sErbB3/NRG1b complex (open green circles) and an EGFsEGFRY251A/R285S complex (open blue squares).increases to 37.8 A˚, similar to the values measured for the
extended sErbB2 monomer (Table 1). In addition, the P(r)
curve for EGF-bound sEGFRY251A/R285S (Figure 4C, openStructure 15, 942–blue squares) closely resembles that seen for both sErbB2
and extended sErbB3, being dominated by a single peak.
Using DAMMIN to reconstruct low-resolution molecular954, August 2007 ª2007 Elsevier Ltd All rights reserved 947
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Conformations of ErbB Receptor EctodomainsFigure 5. Solution Structure of EGF-
Induced sEGFR Dimer
(A) Comparison of P(r) curves measured for an
EGF-induced sEGFR dimer (light blue dia-
monds) and calculated (lines) by using the
model shown in Figure 1. To generate the di-
mer model, domain IV was added to the co-
ordinates (PDB ID 1IVO) for the EGF-induced
dimer of sEGFR501 (Ogiso et al., 2002),
assuming that the domain III/IV relationship is
fixed in the sEGFR dimer and monomer. P(r)
curves were calculated with (black dashed
line) and without (solid gray line) modeled oli-
gosaccharide. An experimental P(r) curve for
monomeric sEGFR (from Figure 2A) is also
overlaid for comparison (black squares).
(B) The model for a ligand-induced sEGFR di-
mer is docked into a DAMMIN-derived molec-
ular envelope generated from SAXS data. Two
orthogonal views are shown.envelopes, the EGF-induced transition of monomeric
sEGFRY251A/R285S from the tethered to an extended
configuration can be visualized clearly (Figure 4D). In
Figure 4E, P(r) curves for sErbB2, EGF-bound sEG-
FRY251A/R285S, and NRG1b-bound sErbB3 are all overlaid.
The similarity of these P(r) curves, together with the simi-
larity of their low-resolution envelopes (Figures 3C, 4B,
and 4D), argues that growth factor binding can drive
sEGFR or sErbB3 into an ErbB2-like extended conforma-
tion even in the absence of dimerization.
Low-Resolution Solution Structure of an Intact
EGF/sEGFR Dimer
The two published crystal structures of growth-factor-
bound sEGFR dimers are missing the majority of domain
IV, either because it was absent from the crystallized pro-
tein (Garrett et al., 2002) or was insufficiently well ordered
to give interpretable electron density (Ogiso et al., 2002).
Prevailing models for full-length sEGFR dimers assume
that the relationship between domains III and IV seen
in the tethered sEGFR structure (Ferguson et al., 2003;
Li et al., 2005b) is maintained following dimerization,948 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd All ralthough this has never been demonstrated experimen-
tally. We were therefore interested to determine whether
such a model for the EGF/sEGFR dimer (as shown in
Figure 1) can adequately account for its experimental
SAXS profile. We previously reported SAXS analysis of a
1:1 complex between wild-type sEGFR (from CHO cells)
and EGF (Lemmon et al., 1997), which gave an Rg value
of 44 A˚ and Dmax of135 A˚. Results using Sf9 cell-derived
protein gave similar values, with Rg measured at 46.1 A˚
and Dmax 145 A˚. Analysis of the structural model shown
in Figure 1 (withmodeled oligosaccharides) usingCRYSOL
gave Rg and Dmax values of 46.8 A˚ and 140 A˚. As shown in
Figure 5A, P(r) curves derived from the structural model
(with and without modeled oligosaccharides) agree quite
well with those observed experimentally, although differ-
ences at longer distances that may reflect a more variable
relationship between domain IV and the rest of the mole-
cule than implied by the static structural model. As shown
in Figure 5B, the model for an intact sEGFR dimer that as-
sumes a fixed domain III/domain IV relationship (and inter-
molecular contacts involving domain IV of each protomer)
is accommodated satisfactorily by the low-resolutionights reserved
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Conformations of ErbB Receptor Ectodomainsmolecular envelope derived from experimental SAXS
studies. Thus, SAXS data provide clear support for the
model of an EGF-induced sEGFR dimer presented in
Figure 1.
Mutations Thought to Disrupt the sEGFR Tether
Promote Only Small Conformational Changes
As mentioned in the introduction, a primary motivation for
our SAXS analysis of sEGFR conformation was the obser-
vation that presumed tether-disrupting mutations do not
cause ligand-independent activation of the receptor at
the cell surface (Ferguson et al., 2003; Mattoon et al.,
2004; Walker et al., 2004). We previously showed that
substituting the three amino acid side chains in domain
IV that form hydrogen bonds with domain II in the intramo-
lecular tether (D563, H566, and K585) increases the EGF
binding affinity of sEGFR by approximately 3-fold (Daw-
son et al., 2005; Ferguson et al., 2003) but does not acti-
vate the receptor or cause sEGFR dimerization without
EGF. The failure of these mutations to activate EGFR
may reflect incomplete disruption of the domain II/IV tether
or might reflect the fact that additional ligand-induced
conformational changes in domain II are required for
EGFR dimerization (Dawson et al., 2005). SAXS analysis
of triply mutated (D563A/H566A/K585A) sEGFR (denoted
sEGFR563/566/585*) gave a Dmax value of 100 A˚ and an Rg
of 36.2 A˚, arguing that it is not significantly changed from
the wild-type protein. The P(r) curve for sEGFR563/566/585*
(Figure 6A) also shares characteristics with that seen for
wild-type sEGFR. The dominant peak in the P(r) curve at
40 A˚ is unchanged, but the shoulder at 60–65 A˚ seen
in all tethered sErbB proteins (Figures 2 and 4 and
Figure S1) is less well defined. The DAMMIN envelope ob-
tained for sEGFR563/566/585* (Figure 6B) also closely re-
sembles that seen for wild-type sEGFR, indicating that
this triple mutation does not greatly alter the conformation
of sEGFR—and is certainly not sufficient to drive sEGFR
into a predominantly extended conformation.
Additional intramolecular interactions that contribute to
the sEGFR tether involve residues 575–584, which com-
prise a loop in the seventh disulfide-bondedmodule of do-
main IV (Ferguson et al., 2003). Deletion of this loop also
elevates EGF binding affinity of sEGFR (by 5-fold) and
does not activate the receptor in the absence of EGF
(Dawson et al., 2005) or promote sEGFR dimerization
(not shown). Based on the sEGFR crystal structure
(Ferguson et al., 2003), simultaneous deletion of the
575–584 loop and mutation of D563, H566, and K585
should abolish all observed tether contacts between do-
mains II and IV. We therefore generated this variant
(sEGFR563/566/585*/D575–584), and analyzed its ligand-
binding and X-ray-scattering properties. As predicted
from our previous studies (Dawson et al., 2005),
sEGFR563/566/585*/D575–584 binds EGF more tightly (KD =
11.5 nM) than sEGFR563/566/585* (KD = 43 nM) or wild-
type sEGFR, for which KD = 143 nM (Figure 6C). A variant
of sEGFR (sEGFR501) that lacks domain IV altogether, so
cannot form any tether interactions, binds EGF with KD =
9 nM, suggesting that the tether is essentially abolishedStructure 15, 942in the sEGFR563/566/585*/D575–584 mutant. Nonetheless, an
EGFR deletion mutant lacking residues 560–590 (and
thus all tether contacts) is not constitutively active and ap-
pears to respond normally to EGF treatment in a cellular
context (Mattoon et al., 2004).
Surprisingly, despite having every tether-contact
residue deleted or mutated, sEGFR563/566/585*/D575–584
closely resembles unliganded wild-type sEGFR in its
SAXS properties (Table 1 and Figure 6). Dmax is 100 A˚
(compared with 100 A˚ for wild-type sEGFR), and Rg is
34.8 A˚ (compared with 35.4 A˚ for wild-type sEGFR). The
P(r) curve for sEGFR563/566/585*/D575–584 is very similar to
that seen for sEGFR563/566/585* and differs from wild-type
sEGFR only in the extent to which the 60–65 A˚ shoulder
is defined (Figure 6A). The DAMMIN-derived molecular
envelope for sEGFR563/566/585*/D575–584 (Figure 6B) is also
indistinguishable from that seen with unliganded wild-
type or sEGFR563/566/585* and is certainly inconsistent
with an extended configuration such as that seen for
sErbB2 or NRG1b-bound sErbB3. Our data therefore sug-
gest that sEGFR remains on average close to the tethered
configuration even when all crystallographically observed
tether contacts have been abolished. The poorer definition
of the 60–65 A˚ shoulder in the P(r) curve is consistent
with a model in which the domain I/II and domain III/IV
parts in Figure 2C are less rigidly fixed with respect to
one another than in the wild-type receptor—allowing
a broader range of interatomic distances for vectors link-
ing these two parts—but have a similar mean relationship
to that seen in wild-type sEGFR. This model would also
account for the remarkably similar molecular envelopes
calculated for wild-type and mutated forms of sEGFR
(Figure 6B).
DISCUSSION
Beyond linking crystallographic observations of ErbB re-
ceptor extracellular regions to their properties in solution,
our SAXS studies provide important new perspectives on
the conformational dynamics of ErbB receptors. First,
simply adopting the extended configuration is not suffi-
cient for dimerization in solution—as exemplified by
sErbB2, NRG1b-bound sErbB3, and EGF-bound sEG-
FRY251A/R285S. In each of these three cases, the receptor
extracellular region (or its complex with ligand) is bothmo-
nomeric and extended. Second, our data argue that the
conserved domain II/IV interactions seen in unliganded
sEGFR (Ferguson et al., 2003; Li et al., 2005b), sErbB3
(Cho and Leahy, 2002), and sErbB4 (Bouyain et al.,
2005) are less important in defining the inactive tethered
conformation than previously supposed (Burgess et al.,
2003). Even with every crystallographically observed do-
main II/IV contact removed by mutation and deletion,
sEGFR563/566/585*/D575–584 remains very close to the teth-
ered conformation. The extended configuration of sEGFR
only predominates following ligand binding.
The fact that unliganded sErbB2 is extended was ini-
tially ascribed in part to the absence of key tether-forming
side chains in domains II or IV (Cho and Leahy, 2002; Cho–954, August 2007 ª2007 Elsevier Ltd All rights reserved 949
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Conformations of ErbB Receptor EctodomainsFigure 6. Mutation of Tether Contacts
Has Little Effect on sEGFR Conformation
(A) SAXS analysis was performed for sEGFR
mutants with mutations in the three residues
that participate in side-chain-mediated hydro-
gen bonds between domains II and IV in the
intramolecular tether (sEGFR563/566/585*), or
with all crystallographically observed (Fergu-
son et al., 2003) tether contacts removed
(sEGFR563/566/585*/D575–584). P(r) curves for
sEGFR563/566/585* (filled gray squares) or
sEGFR563/566/585*/D575–584 (open gray squares)
are very similar to that seen for wild-type
sEGFR (filled black squares)—as are Rg and
Dmax values (Table 1). Although some of the
finer structure of the wild-type P(r) curve is
lost in these mutants, it is clear that their
P(r) curves do not resemble the extended
conformation (seen for sErbB2 with filled red
triangles).
(B) SAXS-derived low-resolution molecular
envelopes are shown for wild-type sEGFR
(left) as well as sEGFR563/566/585* and
sEGFR563/566/585*/D575–584. Each looks similar
and accommodates the tethered sEGFR coor-
dinates but not an extended sErbB configura-
tion. Thus, disrupting the crystallographically
observed tether does not cause sEGFR to
adopt the extended conformation.
(C) SPR analysis shows that
sEGFR563/566/585*/D575–584, in which all ob-
served tether contacts are broken, binds im-
mobilized EGFwith an affinity indistinguishable
from thatmeasured for sEGFR501 (which lacks
domain IV). sEGFR563/566/585*/D575–584 (open
gray squares) binds EGF with a KD of 11.5 ±
2.0 nM, compared with 9.3 ± 1.3 nM for
sEGFR501 (gold diamonds). sEGFR563/566/585*
(filled gray squares) binds EGF a little more
weakly (KD = 43.5 ± 6.6 nM), presumably re-
flecting an incomplete abolition of the tether,
and wild-type sEGFR (filled black squares)
binds EGF with KD = 142.6 ± 8.2 nM.et al., 2003). Our finding that abolishing domain II/IV inter-
actions in sEGFR has little effect on its conformation sug-
gests that sErbB2 is extended not because it lacks tether-
forming interactions, but primarily because it is held in the
extended configuration by direct intramolecular domain I/
III interactions (which bury 1200 A˚2) (Cho et al., 2003;
Franklin et al., 2004; Garrett et al., 2003). In turn, this con-
clusion emphasizes the importance of bivalent EGF bind-
ing to domains I and III in driving (and defining) the ex-
tended conformation of sEGFR that dimerizes. Although
we cannot accurately estimate the fraction of wild-type
sEGFR or sErbB3 that exists in extended conformations
without bound ligand, the remarkable agreement between950 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd All rigexperimental SAXS parameters and those calculated from
the sEGFR and sErbB3 crystal structures (Table 1 and
Figure S2) argues that it must be small.
The fact that mutations presumed to disrupt the domain
II/IV tether in sEGFR do not substantially alter its average
configuration also provides an explanation for why this
tether appeared to ‘‘exert only limited control’’ over recep-
tor function in previously reported signaling experiments
(Ferguson et al., 2003; Mattoon et al., 2004; Walker
et al., 2004). Mutations designed to disrupt the tether
clearly reduce the energetic barrier to bringing domains I
and III sufficiently close to bind a single EGF molecule:
this is reflected in the enhanced EGF-binding affinity (byhts reserved
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Conformations of ErbB Receptor EctodomainsFigure 7. Conserved Relationship between Domains II and III
in All Inactive ErbB and Insulin Receptor Family Extracellular
Region Structures
(A) Structures of the domain I/II/III fragment of sErbB3 (1M6B, green)
and sErbB4 (2AHX, purple) are overlaid on the structure of the tethered
form of sEGFR (1YY9, gray), with the backbone of domain III used as
reference for superimposition. Domains I, II, III and IV are marked,
and disulfides in domain II are drawn (orange). The disulfide corre-
sponding to C305/C309 in human EGFR—at which an activating
mutation was isolated in C. elegans is boxed in red.
(B) Using the backbone of domain III as the reference for superimposi-
tion, the structures (Garrett et al., 1998; Lou et al., 2006) of the domain
I/II/III fragments of the IGF1 receptor (1IGR, yellow) and insulin recep-
tor (2HR7, chain A, cyan) are shown overlaid on tethered sEGFR (1YY9,
gray). Domain II disulfides are colored orange. The domain II/III rela-Structure 15, 9412-fold, or approximately 1.5 kcal/mol) of tether-
mutated sEGFR (Ferguson et al., 2003). However, these
mutations do not ‘‘release’’ the tether, suggesting that
there are further restraints on the domain arrangement of
sEGFR that define the crystallographically observed
tethered configuration. One possibility is that oligosac-
charides, not fully visualized in the crystal structures,
impose steric restraints on the relative positions of do-
mains in the receptors’ extracellular region and that ligand
binding is required to overcome these. For example, there
is an oligosaccharide linked to N337 of EGFR at the do-
main II/III boundary, close to the primary ‘‘hinge’’ for con-
formational changes involved in the tethered-to-extended
transition. This oligosaccharide could sterically restrict the
relative orientation of domains II and III and thus contribute
to maintaining the tethered conformation. Interestingly,
the N337 glycosylation site is conserved in the three
tethered ErbB receptors (EGFR, ErbB3, and ErbB4), but
not in ErbB2. Analyzing the effects of mutating glycosyla-
tion sites on sEGFR conformation should address this
possibility.
A rigid connection between domains II and III could also
stabilize the tethered conformation by restricting rotation
about the hinge shown in Figure 1. Beyond the covalent
linkage of the two domains through the polypeptide back-
bone, there are few (if any) direct interactions between do-
mains II and III that could explain such a restriction in
tethered sErbB structures (see Figure 2C). Despite this
apparent lack of conformational constraints, however,
the relationship between domains II and III is remarkably
well conserved not only across tethered sErbB crystal
structures (Figure 7A), but also across the insulin and insu-
lin-like growth factor (IGF1) receptor families that have no
domain IV with which to form a tether (Figure 7B). The do-
main II/III relationship in IGF1-R and insulin receptor frag-
ments containing only domains I, II, and III is very similar to
that seen in tethered ErbB receptors. The same relation-
ship also exists in the entire insulin receptor extracellular
region (McKern et al., 2006). These observations suggest
that features inherent to the domain II/III linkage must de-
fine the relative orientation of these two domains. A key
feature of this linkage is the most C-terminal disulfide
bond in domain II (C305/C309 in sEGFR), which is boxed
in red in Figures 7A and 7B and overlays remarkably well
between tethered sErbB structures and the IGF1/insulin
receptor family. This disulfide bond may impart rigidity
to the domain II/III linkage and define the trajectory of
tionship is also well conserved in chain B from 2HR7 (insulin receptor)
and in the structure of the intact insulin receptor extracellular region
(PDB ID 2DTG) crystallized in an inactive form (McKern et al., 2006).
These two structures are omitted from the figure for clarity. Note that
domains I and III are termed L1 and L2 respectively in the insulin recep-
tor family, while domain II is termed CR1 (Garrett et al., 1998).
(C) With domain III as the reference for superimposition, the domain I/
II/III fragment of activated, dimeric, sEGFR (1MOX, black) is shown
overlaid on the tethered sEGFR monomer (1YY9, gray). The domain
II/III relationship is dramatically altered, with the domain I/II part of
sEGFR following approximately the trajectory indicated by the arrow.2–954, August 2007 ª2007 Elsevier Ltd All rights reserved 951
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This rigidity may be sufficient to maintain sEGFR (as well
as the IGF1 and insulin receptors) in the tethered configu-
ration even when all domain II/IV tether interactions have
been removed. Indeed, disruption of this disulfide bond
in the C. elegans EGF receptor LET-23 results in a gain-
of-function phenotype. The mutated receptor (C359Y)
promotes vulval induction in homozygous mutant worms
without LIN-3 (Katz et al., 1996) but is clearly not fully ac-
tivated since it can still respond robustly to ligand or to fur-
ther activation by other LET-23 mutations (Katz et al.,
1996; Moghal and Sternberg, 2003).
We suggest that the tethered configuration of the EGFR
extracellular region is stabilized by multiple interactions
that include intramolecular domain II/IV interactions (the
crystallographically defined tether), backbone rigidity in
the domain II/III linkage (contributed to by the C305/
C309 disulfide bond), and additional possible steric re-
straints imposed by oligosaccharides. To fully activate
the receptor, all of these interactions must be overcome
simultaneously—with ligand (or domain I/III interactions)
bringing domains I and III into close proximity to drive
the receptor into an extended state. Disrupting any one
set of interactions in isolation will likely not lead to full ac-
tivation without ligand. Indeed, a C305Y mutation in hu-
man EGFR (equivalent to C359Y in C. elegans EGFR) did
not cause ligand-independent receptor activation in bio-
chemical assays (Katz et al., 1996), and neither does abla-
tion of all crystallographically observed domain II/IV tether
interactions (Ferguson et al., 2003; Mattoon et al., 2004;
Walker et al., 2004). However, a small degree of receptor
activation by these mutations may have phenotypic con-
sequences—as observed with the C359Y mutation in
C. elegans EGFR (Katz et al., 1996). Several mutations in
the extracellular region of human EGFR were recently
found in glioma samples and glioblastoma cell lines (Lee
et al., 2006), and it was suggested that some of these
might elevate EGFR signaling by destabilizing the tethered
conformation. One of these mutations (T239P) is close to
the domain II/IV interface (although T239 does not partic-
ipate in direct interactions) and did not cause significant
elevation in biochemical studies of EGF-independent re-
ceptor phosphorylation (Lee et al., 2006). Two mutations
in domain IV (P572L and G574V) could also influence the
conformation of the 575–584 loop that contributes to the
domain II/IV tether. However, they could equally well
cause misfolding of the receptor in the endoplasmic retic-
ulum (and cell-surface expression was not assessed),
which has been shown to result in constitutive oncogenic
signaling in other ErbB receptor studies (Hudziak and
Ullrich, 1991).
In conclusion, our findings suggest that theautoinhibited
or tethered conformation of ErbB receptor extracellular re-
gions depends on multiple weak interactions spread over
several parts of the protein. As expected for a robust
mechanism of autoinhibition, mutation of no single set of
interactions fully deregulates the receptor but may have
phenotypic consequences that arise fromsmall destabiliz-
ing effects on the tethered conformation of EGFR.952 Structure 15, 942–954, August 2007 ª2007 Elsevier Ltd AllEXPERIMENTAL PROCEDURES
Protein Production and Purification
All variants of human sEGFR (residues 1–642 of pro-sEGFR or 1–618 of
the mature sequence) and human sErbB3 (residues 1–639 of pro-
sErbB3 or 1–620 of the mature protein) were expressed in Sf9 cells in-
fected with the appropriate recombinant baculovirus and were purified
exactly as described previously (Ferguson et al., 2003; Ferguson et al.,
2000). Human sErbB2 was produced by secretion from S2 cells stably
transfected with a derivative of pMT/V5-HisA (Invitrogen) containing
DNA-encoding residues 1–647 of pro-sErbB2 (1–628 of the mature
protein). Expression of sErbB2 was induced with 500 mM copper sul-
fate, and sErbB2 purification followed the procedure described previ-
ously for D. melanogaster sEGFR (Klein et al., 2004). In cases where
growth factor ligand (EGF or NRG1b) was added, ligands were added
to a 1.2-fold molar excess. EGF was purchased from Chemicon, Inc.,
and NRG1b was purchased from R&D Systems. All proteins and li-
gand/receptor mixtures were dialyzed against 25 mM HEPES, 150
mM NaCl (pH 8.0). The dialysis buffer was then used as a blank in
SAXS experiments. All protein solutions were filtered with prewashed
0.22 mm polycarbonate filters (Spin-X, Corning) before measurements
were taken. Previous analytical ultracentrifugation and SAXS studies
have shown that sEGFR (and the various mutants), sErbB2, and
sErbB3 are monomeric under the experimental conditions employed
here (Dawson et al., 2005; Ferguson et al., 2000; Lemmon et al., 1997).
Small-Angle X-Ray Scattering
Small-angle X-ray scattering (SAXS) data were measured with an in-
house apparatus utilizing a MicroMaxTM-007 HF Microfocus genera-
tor (Rigaku/MSC, Texas) as the X-ray source (Li et al., 2005a), and
a two-dimensionalmultiwire detector (MolecularMetrology) with a sen-
sitive diameter of 20 cm. Data were circularly averaged and converted
to plots of I(Q) against Q with software written in house. In the present
study, a 0.013 < Q < 0.30 A˚1 range is covered, whereQ = 4p sin(q/2)/l
is the magnitude of the scattering vector, q is the scattering angle, and
l is the X-ray wavelength. Protein samples at concentrations from 1–2
mg/ml (11–23 mM) were placed in a 2 mm glass capillary cell as
described (Bu et al., 1998), and SAXS data were collected for 3–4 hr
at room temperature on both samples and matched buffer back-
ground. Intensity data were reduced by standard procedures. Normal-
ized scattering by the buffer blank was then subtracted from
scattering by the protein sample to give the net scattering by the
protein component.
SAXS Data Analysis and Modeling
Reduced scattering data were plotted as scattered intensity (I(Q))
against Q profiles, as shown in Figure 3A. For each sample the radius
of gyration (Rg), which reflects the spatial extent of the protein, can be
evaluated by using the Guinier approximation (Cantor and Schimmel,
1980): ln I(Q) = ln I(0)  (1/3)Q2Rg2, by fitting data in the QRg < 1 region
to a straight line (see Figure 2D). Rg can also be obtained by evaluating
the second moment of the P(r), or length distribution, function. P(r) de-
scribes the probability of finding two scattering points at a given dis-
tance r from one other in the macromolecule of interest and is obtained
by inverse Fourier transformation of I(Q). The program GNOM (Sver-
gun, 1992) was used to calculate P(r) andRg from the scattering curves
by using the indirect transform method. Values for Dmax, the maximum
dimension of the macromolecule, were determined empirically by re-
computing P(r) curves in GNOM with a series of different rmax values
(in steps of 5 A˚), and selecting as Dmax the rmax value at which P(r)
most closely approached zero while giving a plausible P(r) curve.
Values of Rg are listed in Table 1 and the text with errors estimated
by GNOM. Errors in Dmax values are quoted as ±5 A˚ based on the
empirical approach used for their determination.
To evaluate Rg and Dmax values for crystal structures (or models) of
ErbB receptor extracellular regions, the program CRYSOL (Svergun
et al., 1995) was used to generate a predicted scattering curve, which
was then analyzed by using GNOM as described above. Torights reserved
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oligosaccharide moieties were manually docked onto known (Zhen
et al., 2003) or presumed glycosylation sites. Coordinates for the
Man9GlcNAc2 moiety were taken from a Man7GlcNAc2 moiety that
was well defined in one set of coordinates (1YY9) for tethered sEGFR
(Li et al., 2005b). Two additional mannose residues were added, and
the resulting Man9GlcNAc2 moiety was attached manually to each
glycosylated Asn side chain, projecting along an axis approximately
perpendicular to the surface of the protein at the glycosylation site.
Low-resolution ab initio molecular envelopes were generated with
the program DAMMIN (Svergun, 1999), which uses simulated anneal-
ing to identify arrangements of densely packed dummy atoms that fit
the observed SAXS data while minimizing the interfacial area. At least
ten iterations of DAMMIN were run for each protein sample by using
the ‘‘fast’’ annealing mode with default parameters to avoid shape
bias and by using data with Q < 0.20A˚1. This provided an ensemble
of possible shapes that were aligned and used to build the ‘‘most prob-
able’’ model with the DAMAVER suite of programs (Volkov and Sver-
gun, 2003). Outlier shapes with particularly high NSD values (for nor-
malized spatial discrepancy) were discarded as described (Volkov
and Svergun, 2003), and the remainder were averaged to compute
a probability map that was filtered with DAMFILT to give an envelope
corresponding to the most probable model. The relevant crystal struc-
ture was then docked into this low-resolution molecular envelope with
the program Situs (Wriggers and Birmanns, 2001), and the best fit was
visualized with the program VMD (Humphrey et al., 1996).
Surface Plasmon Resonance Studies
EGF and TGFa binding by sEGFR variants was examined by surface
plasmon resonance (SPR) experiments performed exactly as de-
scribed (Dawson et al., 2005; Ferguson et al., 2003). Binding experi-
ments were performed in degassed 25mMHEPES buffer (pH 8.0) con-
taining 150 mM NaCl, 3 mM EDTA, and 0.005% Surfactant P-20 at
25C. EGF and TGFa were immobilized on Biacore CM5 biosensor
chips by amine coupling, and purified sEGFR proteins were flowed
across the resulting surfaces (plus a control surface with no immobi-
lized ligand) at a series of concentrations at 10 ml/min for 20 min (which
was sufficient time for binding to reach a plateau). Between experi-
ments, ligand surfaces were subjected to a regeneration/wash injec-
tion (10 mM sodium acetate, 1 M NaCl [pH 5.2]). Sensorgrams were
background corrected, and the maximal steady state SPR signals de-
termined for a range of sEGFR concentrations were fit to a simple bind-
ing curve as previously described (Ferguson et al., 2000) to estimate
the dissociation constant (KD). Each experiment was performed at
least in triplicate, with the mean and standard deviation of KD values
quoted in the legend to Figure 6.
Supplemental Data
Supplemental Data include an analysis of the effects of glycosylation
on calculated P(r) curves (Figure S1) and direct comparison/overlays
of calculated and experimental P(r) curves for EGFR, ErbB2, and
ErbB3 (Figure S2) and are available at http://www.structure.org/cgi/
content/full/15/8/942/DC1/.
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